Key terms
About IMCR
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IMCR news
Apr 29
6:28am ET
Immunocore initiated with an Outperform at Leerink
Apr 05
3:50am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
Apr 03
7:40am ET
Analysts Offer Insights on Healthcare Companies: High Tide (HITI), Venus Concept (VERO) and Immunocore Holdings (IMCR)
Mar 21
6:05am ET
Immunocore files automatic mixed securities shelf
Mar 06
9:15am ET
Buy Rating on Immunocore Holdings: Robust Financials and Promising Pipeline Signal Growth
Mar 06
6:40am ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
Mar 05
6:41am ET
Immunocore price target raised to $90 from $86 at Mizuho
Mar 01
1:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Oculis Holding (OCS)
Feb 29
8:40am ET
Immunocore price target raised to $87 from $85 at Oppenheimer
Feb 29
8:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)
Feb 29
8:02am ET
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Feb 29
6:37am ET
Immunocore Holdings: A Strong Buy on Robust KIMMTRAK Sales and Promising Clinical Milestones
Feb 29
6:30am ET
Immunocore Holdings (IMCR) Gets a Buy from Barclays
Feb 28
10:10pm ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Immunocore Holdings (IMCR)
Feb 28
4:46pm ET
Immunocore Holdings Q4 and Full-Year 2023 Earnings Presentation
Feb 28
4:30pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 28
12:10pm ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)
Feb 28
7:35am ET
Immunocore reports Q4 EPS (40c), consensus (28c)
Feb 22
7:18am ET
Immunocore enters trial collaboration, supply agreement with Bristol Myers
Feb 15
6:47am ET
Immunocore price target raised to $86 from $72 at Mizuho
Feb 05
4:40am ET
Analysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)
No recent press releases are available for IMCR
IMCR Financials
Key terms
Ad Feedback
IMCR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IMCR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
